Agenus Q3 2026 net income drops 96% year over year to $2.8 million

Bitget2026/11/05 12:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Agenus’ third-quarter 2026 net income fell 96% year over year to $2.8 million; revenue rose to $31.5 million.
Cash, cash equivalents and short-term investments increased from the previous quarter to $86.9 million at September 30, 2026.
Armenia granted the first worldwide marketing authorizations for botensilimab and balstilimab, each for use in combination with the other.
The Phase 3 ROBBIN trial remains on track for first patient enrollment in Q1 2027.
July financing proceeds are expected to support operations through Q3 2027, extending through year-end 2031 if milestone-aligned warrants are fully exercised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050730BIZWIRE_USPR_____20261105_BW453521) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Agenus Q3 2026 net income drops 96% year over year to $2.8 million

You may also like

Crypto prices